Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMC-CLI
- Development stage
- Unknown
- Lead developer
- ThermoGenesis
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
BMC-CLI (also known as SurgWerks-CLI) is an autologous bone marrow stem cell therapy being developed by ThermoGenesis (formerly Cesca Therapeutics) and Beijing Boya Research Institution (via its TG Medical subsidiary) for the treatment of critical limb ischemia (CLI) and lower limb ischemic disease. The therapy involves harvesting bone marrow from the patient, processing it at the point-of-care using the proprietary SurgWerks-CLI kit and VXP system to produce a highly concentrated autologous bone marrow cell (aBMC) formulation, and then intramuscularly injecting the cells into the ischemic lower limb. The transplanted stem and progenitor cells are intended to promote neovascularization, stimulate blood vessel regeneration, and improve blood circulation, thereby preventing major limb amputation in patients with advanced, non-reconstructable CLI. The therapy is currently in Phase 3 clinical development.
- Other names
- Autologous Bone Marrow Stem Cell TherapyAutologous bone marrow stem cells for critical limb ischemiaSurgWerks-CLIaBMCautologous bone marrow cell concentrate
Beyond the preview
Go deeper on BMC-CLI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMC-CLI.